

## UTILIZATION MANAGEMENT MEDICAL POLICY

- POLICY:** Ophthalmology – Vascular Endothelial Growth Factor Inhibitors – Eylea and Eylea HD Utilization Management Medical Policy
- Eylea® (aflibercept intravitreal injection – Regeneron)
  - Eylea® HD (aflibercept intravitreal injection – Regeneron)

**REVIEW DATE:** 11/15/2023

---

### OVERVIEW

Eylea, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the following uses:<sup>1</sup>

- **Diabetic macular edema.**
- **Diabetic retinopathy.**
- **Macular edema following retinal vein occlusion.**
- **Neovascular (wet) age-related macular degeneration.**
- **Retinopathy of Prematurity.**

Eylea HD, a high dose VEGF inhibitor, is indicated for the following uses:<sup>6</sup>

- **Diabetic macular edema.**
- **Diabetic retinopathy.**
- **Neovascular (wet) age-related macular degeneration.**

### Dosing Information:

Eylea: For all of the indications, except retinopathy of prematurity, the recommended dose for Eylea is 2 mg administered by intravitreal injection.<sup>1</sup> The frequency of dosing depends on the indication and patient response. Some patients require every 4 week dosing (approximately every 25 days, monthly). The dose for retinopathy of prematurity is 0.4 mg administered by intravitreal injection; repeat injections may be given and the treatment interval between doses injected into the same eye should be at least 10 days.

Eylea HD: For all indications, the recommended dose for Eylea HD is 8mg administered by intravitreal injection.<sup>6</sup> For diabetic macular edema and neovascular (wet) age-related macular degeneration, the dosing regimen for Eylea HD is once every 4 weeks (approximately every 28 days +/- 7 day) for the first three doses, followed by one dose every 8 to 16 weeks, +/- 1 week. For diabetic retinopathy, the dosing is every 4 weeks (approximately every 28 days +/- 7 day) for the first three doses, followed by one dose every 8 to 12 weeks, +/- 1 week.

### Other Uses with Supportive Evidence for Eylea

Overproduction of VEGF may lead to other eye conditions, including neovascular glaucoma and other retinal and choroidal neovascular conditions affecting the eye.<sup>2,3</sup> The VEGF inhibitors have the potential to be used off-label to reduce or slow visual impairment or vision loss associated with other eye conditions related to increased VEGF production.<sup>2,4,5</sup> The use of anti-VEGF agents have been shown to stop the angiogenic process and maintain visual acuity and improve vision in patients with certain neovascular ophthalmic conditions; therefore, research is rapidly evolving on the use of VEGF inhibitors in other neovascular ophthalmic conditions which threaten vision.<sup>4,5</sup>

## POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of Eylea and Eylea HD. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indications. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Eylea and Eylea HD as well as the monitoring required for adverse events and long-term efficacy, approval requires Eylea and Eylea HD to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Automation:** None.

## RECOMMENDED AUTHORIZATION CRITERIA

I. Coverage of Eylea is recommended in those who meet one of the following criteria:

### FDA-Approved Indications

- 
1. **Diabetic Macular Edema.** Approve for 1 year if administered by or under the supervision of an ophthalmologist.

**Dosing.** Approve if the dose meets both of the following (A and B):

- A) The dose is 2 mg administered by intravitreal injection for each eye being treated; AND  
B) The dosing interval is not more frequent than once every 25 days for each eye being treated.

- 
2. **Diabetic Retinopathy.** Approve for 1 year if administered by or under the supervision of an ophthalmologist.

**Dosing.** Approve if the dose meets both of the following (A and B):

- A) The dose is 2 mg administered by intravitreal injection for each eye being treated; AND  
B) The dosing interval is not more frequent than once every 25 days for each eye being treated.

- 
3. **Macular Edema Following Retinal Vein Occlusion.** Approve for 1 year if administered by or under the supervision of an ophthalmologist.

**Dosing.** Approve if the dose meets both of the following (A and B):

- A) The dose is 2 mg administered by intravitreal injection for each eye being treated; AND  
B) The dosing interval is not more frequent than once every 25 days for each eye being treated.

- 
4. **Neovascular (Wet) Age-Related Macular Degeneration.** Approve for 1 year if administered by or under the supervision of an ophthalmologist.

**Dosing.** Approve if the dose meets both of the following (A and B):

- A) The dose is 2 mg administered by intravitreal injection for each eye being treated; AND

- B) The dosing interval is not more frequent than once every 25 days for each eye being treated.

---

**5. Retinopathy of Prematurity.** Approve for 1 year if administered by or under the supervision of an ophthalmologist.

**Dosing.** Approve if the dose meets both of the following (A and B):

- A) The dose is 0.4 mg administered by intravitreal injection for each eye being treated; AND  
B) The dosing interval is not more frequent than once every 10 days for each eye being treated.

**Other Uses with Supportive Evidence**

---

**6. Other Neovascular Diseases of the Eye.** Approve for 1 year if administered by or under the supervision of an ophthalmologist.

Note: Examples of other neovascular diseases of the eye include neovascular glaucoma, sickle cell neovascularization, and choroidal neovascular conditions.

**Dosing.** Approve if the dose meets both of the following (A and B):

- A) The dose is 2 mg administered by intravitreal injection for each eye being treated; AND  
B) The dosing interval is not more frequent than once every 25 days for each eye being treated.

II. Coverage of Eylea HD is recommended in those who meet one of the following criteria:

**FDA-Approved Indications**

---

**1. Diabetic Macular Edema.** Approve for 1 year if administered by or under the supervision of an ophthalmologist.

**Dosing.** Approve if the dose meets both of the following (A and B):

- A) The dose is 8 mg administered by intravitreal injection for each eye being treated; AND  
B) The dosing interval is not more frequent than once every 21 days for three doses, followed by not more frequent than once every 7 weeks for each eye being treated.

Note: The recommended dose is once every 4 weeks (approximately every 28 days +/- 7 day) for the first three doses, followed by one dose every 8 to 16 weeks, +/- 1 week.

---

**2. Diabetic Retinopathy.** Approve for 1 year if administered by or under the supervision of an ophthalmologist.

**Dosing.** Approve if the dose meets both of the following (A and B):

- A) The dose is 8 mg administered by intravitreal injection for each eye being treated; AND  
B) The dosing interval is not more frequent than once every 21 days for three doses, followed by not more frequent than once every 7 weeks for each eye being treated.

Note: The recommended dose is once every 4 weeks (approximately every 28 days +/- 7 day) for the first three doses, followed by one dose every 8 to 12 weeks, +/- 1 week.

3. **Neovascular (Wet) Age-Related Macular Degeneration.** Approve for 1 year if administered by or under the supervision of an ophthalmologist.

**Dosing.** Approve if the dose meets both of the following (A and B):

- A) The dose is 8 mg administered by intravitreal injection for each eye being treated; AND  
B) The dosing interval is not more frequent than once every 21 days for three doses, followed by not more frequent than once every 7 weeks for each eye being treated.

Note: The recommended dose is once every 4 weeks (approximately every 28 days +/- 7 day) for the first three doses, followed by one dose every 8 to 16 weeks, +/- 1 week.

---

#### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Eylea and Eylea HD is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

#### REFERENCES

1. Eylea® intravitreal injection [prescribing information]. Tarrytown, NY: Regeneron; August 2023.
2. Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. *Expert Opin Investig Drugs*. 2009;18(5):637-646.
3. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. *Surv Ophthalmol*. 2011;56(2):95-113.
4. Kinnunen K, Ylä-Herttuala S. Vascular endothelial growth factors in retinal and choroidal neovascular diseases. *Ann Med*. 2012;44(1):1-17.
5. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. *Curr Opin Ophthalmol*. 2010;21(2):112-117.
6. Eylea® HD intravitreal injection [prescribing information]. Tarrytown, NY: Regeneron; August 2023.

#### HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	11/16/2022
Selected Revision	<b>Retinopathy of Prematurity:</b> This condition was moved to the FDA-Approved Indications; previously, it was included in the Note of examples of Other Neovascular Diseases of the Eye, under “Other Uses with Supportive Evidence”. For this indication, the dosing was changed to be 0.4 mg administered per injection, with the dosing interval changed to be not more frequent than once every 10 days for each eye being treated (previously, it was the same as Other Neovascular Diseases of the Eye, which was 2 mg per treated eye, with a dosing interval of at least 25 days between doses).	02/22/2023
Selected Revision	<b>Eylea HD:</b> Eylea HD was added to the policy; conditions and criteria for approval were added to the policy.	08/30/2023
Annual Revision	No criteria changes.	11/15/2023